|
| | SR1369 | | LRB100 19627 ALS 34900 r |
|
|
| 1 | | SENATE RESOLUTION
|
| 2 | | WHEREAS, Eczema is a set of skin conditions that cause red, |
| 3 | | itchy, and inflamed skin, and has profound medical, |
| 4 | | psychosocial, and economic effects on patients, families, and |
| 5 | | their communities; and
|
| 6 | | WHEREAS, The prevalence of eczema in the United States is |
| 7 | | 10.1 percent; and
|
| 8 | | WHEREAS, Eczema affects over 31.6 million children and |
| 9 | | adults in the United States alone; and
|
| 10 | | WHEREAS, Eczema's medical effects include dry, cracked, |
| 11 | | and scaly skin, incessant itch, chronic pain, and sleep |
| 12 | | deprivation; and
|
| 13 | | WHEREAS, 41.5 percent of adult eczema patients report |
| 14 | | having a co-occurring diagnosis of depression and 47.9 percent |
| 15 | | report having a co-occurring diagnosis of asthma; and
|
| 16 | | WHEREAS, Adults and children with eczema also frequently |
| 17 | | exhibit comorbidities like asthma, allergic rhinitis, food |
| 18 | | allergies, ADHD, bacterial and viral infections, and |
| 19 | | hypertension; and
|
|
| | SR1369 | - 2 - | LRB100 19627 ALS 34900 r |
|
|
| 1 | | WHEREAS, Eczema's disease burden also includes anxiety, |
| 2 | | stress on social and intimate relationships, increased |
| 3 | | suicidal ideation, delayed developmental achievement, reduced |
| 4 | | self-esteem, restrictions on diet and exercise, extensive |
| 5 | | caregiver burdens, and challenges with medication adherence; |
| 6 | | and
|
| 7 | | WHEREAS, Eczema results in missed days of school and work |
| 8 | | for patients and caregivers, disability, and reduced ability |
| 9 | | within a patient's chosen profession, unemployment and |
| 10 | | underemployment, and other opportunity costs; and
|
| 11 | | WHEREAS, The direct medical costs of the three most common |
| 12 | | types of eczema exceed $2.17 billion, and the indirect medical |
| 13 | | costs exceed $927 million; and
|
| 14 | | WHEREAS, Two-thirds of eczema patients report experiencing |
| 15 | | significant access barriers, including high out-of-pocket |
| 16 | | costs and insurance requirements that delay patients' access to |
| 17 | | medications; and
|
| 18 | | WHEREAS, There is no cure for eczema, but emerging |
| 19 | | technologies and medications promise a much brighter future for |
| 20 | | eczema patients; therefore, be it
|
| 21 | | RESOLVED, BY THE SENATE OF THE ONE HUNDREDTH GENERAL |